Cipla Discloses Additional Global Investment, $136 Million In U.K. Unit
This article was originally published in PharmAsia News
Executive Summary
Cipla said it plans to invest about $136 million over the next few years in its U.K. unit to boost its ability to produce a broader range of medicines, including treatments for cancer, HIV/AIDS and respiratory diseases.